Cooper Companies (NASDAQ:COO) Coverage Initiated by Analysts at The Goldman Sachs Group

Equities researchers at The Goldman Sachs Group began coverage on shares of Cooper Companies (NASDAQ:COO) in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The firm set a “sell” rating on the medical device company’s stock.

Several other analysts have also weighed in on the stock. Loop Capital set a $100.00 target price on shares of Cooper Companies in a research note on Tuesday, June 17th. Robert W. Baird dropped their price objective on Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, August 28th. BNP Paribas raised Cooper Companies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 22nd. Needham & Company LLC reissued a “buy” rating and set a $94.00 price objective on shares of Cooper Companies in a report on Thursday, August 28th. Finally, UBS Group upgraded Cooper Companies to a “buy” rating in a research note on Tuesday, June 17th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.75.

Cooper Companies Stock Up 1.5%

Shares of NASDAQ:COO opened at $69.12 on Wednesday. The stock has a market cap of $13.74 billion, a P/E ratio of 34.05, a P/E/G ratio of 1.79 and a beta of 1.02. The firm has a fifty day moving average price of $69.77 and a 200 day moving average price of $74.22. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. Cooper Companies has a 1-year low of $61.78 and a 1-year high of $109.37.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.96 EPS. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Sell-side analysts predict that Cooper Companies will post 3.98 EPS for the current year.

Cooper Companies declared that its board has authorized a stock buyback program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical device company to buy up to 15.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Cooper Companies

In other news, COO Daniel G. Mcbride acquired 3,000 shares of Cooper Companies stock in a transaction dated Tuesday, September 2nd. The shares were purchased at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the transaction, the chief operating officer owned 63,120 shares of the company’s stock, valued at $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Gerard H. Warner III bought 1,450 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The shares were bought at an average price of $69.23 per share, with a total value of $100,383.50. Following the completion of the acquisition, the chief operating officer directly owned 18,319 shares in the company, valued at $1,268,224.37. This trade represents a 8.60% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 17,975 shares of company stock worth $1,216,346 in the last three months. 1.98% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COO. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Cooper Companies by 3.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 9,370 shares of the medical device company’s stock worth $861,000 after purchasing an additional 309 shares in the last quarter. GAMMA Investing LLC lifted its position in Cooper Companies by 5,733.1% during the first quarter. GAMMA Investing LLC now owns 210,285 shares of the medical device company’s stock valued at $17,738,000 after purchasing an additional 206,680 shares in the last quarter. Thrive Wealth Management LLC lifted its position in shares of Cooper Companies by 11.4% in the first quarter. Thrive Wealth Management LLC now owns 3,659 shares of the medical device company’s stock valued at $309,000 after acquiring an additional 373 shares in the last quarter. Impact Capital Partners LLC increased its holdings in shares of Cooper Companies by 4.4% in the first quarter. Impact Capital Partners LLC now owns 8,416 shares of the medical device company’s stock worth $710,000 after purchasing an additional 352 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in Cooper Companies by 16.7% during the first quarter. UMB Bank n.a. now owns 902 shares of the medical device company’s stock worth $76,000 after acquiring an additional 129 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.